P49 Evaluation of Surrogate Endpoints (SES) for Previously Untreated Unresectable or Metastatic Melanoma (MMEL): Analyses from a Longitudinal Electronic Health Record Database in the United States (US)

L. Leung,P. Mohr, P. Serafini, S. Kanters, M.M. Pourrahmat,A. Moshyk,S. Srinivasan,M. Kurt

Value in Health（2023）

引用 0|浏览6

暂无评分

摘要

To evaluate progression-free survival (PFS), time-to-progression (TTP), time-to-next-treatment-or-death (TNTD), and time-to-treatment discontinuation (TTD) as SEs for overall survival (OS) in previously untreated unresectable or mMel in real-world settings.

查看译文

关键词

metastatic melanoma,surrogate endpoints

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要